- Trials with a EudraCT protocol (310)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
310 result(s) found for: Lung compliance.
Displaying page 1 of 16.
EudraCT Number: 2020-002773-10 | Sponsor Protocol Number: IRFMN-LUNG-8287 | Start Date*: 2022-03-14 | ||||||||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | ||||||||||||||||||
Full Title: A phase III prevention trial of canakinumab in subjects at high risk for lung cancer | ||||||||||||||||||
Medical condition: Subjects at high risk for lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000130-11 | Sponsor Protocol Number: EryDexFCTx1.0 | Start Date*: 2011-07-25 | ||||||||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | ||||||||||||||||||
Full Title: Clinical trials in rare diseases: therapeutic alternative to the use of oral corticosteroids in patients with cystic fibrosis underwent double lung transplantation. | ||||||||||||||||||
Medical condition: Double lung transplantation in patients with Cystic Fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000659-23 | Sponsor Protocol Number: 220365-2017 | Start Date*: 2017-10-11 | ||||||||||||||||
Sponsor Name:Aarhus University Hospital | ||||||||||||||||||
Full Title: A Safety and feasibility study of standard dosing day 1 carboplatin AUC 5 every 3rd weeks with daily Navelbine® 20/30mg (oral) during 4 cycles (12 weeks) for the treatment of advanced NSCLC; A feas... | ||||||||||||||||||
Medical condition: Patients with metastatic or locally advanced Non-small-cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-006454-30 | Sponsor Protocol Number: 23537 | Start Date*: 2023-02-09 | ||||||||||||||||
Sponsor Name:DIPARTIMENTO DI SCIENZE CHIRURGICHE - UNIVERSITà DEGLI STUDI DI TORINO | ||||||||||||||||||
Full Title: Near-infrared molecular imaging for lung cancer detection and treatment during mini-invasive surgery (Phase II Trial) | ||||||||||||||||||
Medical condition: To date, lung resection and lymphadenectomy remains the best curative option in patients with early-stage non-small cell lung cancer. Moreover, cancer screening programs have led to a frequent diag... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003608-19 | Sponsor Protocol Number: UCL/09/0426 | Start Date*: 2011-12-19 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Trial of afatinib (BIBW 2992) in suspected or confirmed mutant EGFR lung cancer patients unfit for chemotherapy | |||||||||||||
Medical condition: Non small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005566-39 | Sponsor Protocol Number: 06_DOG07_64 | Start Date*: 2008-03-05 | ||||||||||||||||
Sponsor Name:Christie Hospital NHS Foundation Trust | ||||||||||||||||||
Full Title: Concurrent chemoradiotherapy for stage III non small cell lung cancer followed by consolidation pemetrexed: a phase II study | ||||||||||||||||||
Medical condition: Non-small cell lung cancer, stage III | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022897-14 | Sponsor Protocol Number: PreMENAC-2011-01 | Start Date*: 2011-05-02 |
Sponsor Name:Dep. of Cancer Research and Molecular medicine, Norwegian University of Science and Technology | ||
Full Title: PreMENAC: Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia: A feasibility study (phase II) | ||
Medical condition: Diagnosis of non operable non-small cell lung cancer NSCLC (stage III-IV) or pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) GB (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-002411-36 | Sponsor Protocol Number: CRO756 | Start Date*: 2007-11-01 | ||||||||||||||||
Sponsor Name:Imperial College, London | ||||||||||||||||||
Full Title: LungstarPK: Multi centre Phase II Trial of Pravastatin added to chemotherapy with Cisplatin and Docetaxel in patients with non-small cell lung cancer. | ||||||||||||||||||
Medical condition: non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2021-005136-34 | Sponsor Protocol Number: THIO101 | Start Date*: 2022-11-16 | |||||||||||||||||||||
Sponsor Name:MAIA Biotechnology, Inc. | |||||||||||||||||||||||
Full Title: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-009315-22 | Sponsor Protocol Number: NVALT10 | Start Date*: 2009-02-25 | ||||||||||||||||
Sponsor Name:NVALT | ||||||||||||||||||
Full Title: A randomized phase II study of erlotinib compared to single agent chemotherapy-erlotinib combination in pretreated patients with advanced NSCLC (NVALT10 study) | ||||||||||||||||||
Medical condition: patients who failed previous cytotoxic treatment for non-small-cell lung cancer locally advanced and metastatic disease stage IIIB and IV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001263-12 | Sponsor Protocol Number: FoRT01/2014 | Start Date*: 2014-08-07 | |||||||||||
Sponsor Name:Fondazione Ricerca Traslazionale (FoRT) | |||||||||||||
Full Title: Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS) | |||||||||||||
Medical condition: Pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020229-42 | Sponsor Protocol Number: ML21869 | Start Date*: 2010-07-18 | ||||||||||||||||
Sponsor Name:ROCHE | ||||||||||||||||||
Full Title: A randomized phase II trial of erlotinib (TARCEVA) or intermittent dosing of erlotinib and docetaxel in male former smokers with locally advanced or metastatic squamous nonsmall cell lung cancer... | ||||||||||||||||||
Medical condition: Non-small cell lung cancer (NSCLC), locally advanced (stage IIIB), metastatic (stage IV) or recurrent. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000439-24 | Sponsor Protocol Number: NORA Trial | Start Date*: 2007-02-21 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: NORA TRIAL (oral Navelbine in adjuvabt):multicenter,prospective,phase II, randomized clinical trial concerning about adjuvant chemioterapy with cisplatino and vinorelbine according to an advanced s... | |||||||||||||
Medical condition: patients underwent complete surgery for non small cel lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002050-78 | Sponsor Protocol Number: NVALT-21 | Start Date*: 2014-01-10 | |||||||||||
Sponsor Name:NVALT | |||||||||||||
Full Title: A Phase III, randomised trial of adding nitroglycerin to first line chemotherapy for advanced nonsmall cell lung cancer | |||||||||||||
Medical condition: advanced non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022021-15 | Sponsor Protocol Number: 2010-022021-15 | Start Date*: 2011-02-16 | ||||||||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | ||||||||||||||||||
Full Title: RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III, SUPERIORITY TRIAL TO ASSESS THE EFFICACY AND SAFETY OF ACETYL-L-CARNITINE IN COMBINATION WITH A ... | ||||||||||||||||||
Medical condition: Patients with histologically documented, locally advanced (stage IIIB with either pleural effusion or supra-clavicular nodal disease) or metastatic (stage IV) or recurred after an adjuvant treatmen... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000556-35 | Sponsor Protocol Number: D910LC00001 | Start Date*: 2020-12-01 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected ... | |||||||||||||
Medical condition: Completely Resected Stage II-III NSCLC | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) DK (Prematurely Ended) BG (Completed) HU (Prematurely Ended) DE (Completed) BE (Completed) SE (Prematurely Ended) PL (Completed) CZ (Completed) GR (Completed) IT (Prematurely Ended) FR (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001331-36 | Sponsor Protocol Number: EORTC 08021 - ILCP | Start Date*: 2005-02-17 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: A randomized phase III study of follow-up with or without Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer. | |||||||||||||
Medical condition: Non small cell lung cancer, advanced. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001259-34 | Sponsor Protocol Number: FoRT01/2016 | Start Date*: 2016-08-31 | ||||||||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | ||||||||||||||||||
Full Title: PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST) | ||||||||||||||||||
Medical condition: ROS1 positive non-small-cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004157-16 | Sponsor Protocol Number: CABinMET | Start Date*: 2018-02-21 | ||||||||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT) | ||||||||||||||||||
Full Title: Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation | ||||||||||||||||||
Medical condition: Stage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002934-40 | Sponsor Protocol Number: 2608 | Start Date*: 2006-06-27 | |||||||||||
Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE | |||||||||||||
Full Title: RANDOMIZED PHASE II TRIAL OF FIRST LINE CISPLATIN WITH DOCETAXEL OR VINORELBINE FOR 6 CYCLES IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER | |||||||||||||
Medical condition: PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
